Cargando…

Overexpression of RBBP6, Alone or Combined with Mutant TP53, Is Predictive of Poor Prognosis in Colon Cancer

Retinoblastoma binding protein 6 (RBBP6) plays an important role in chaperone-mediated ubiquitination and interacts with TP53 in carcinogenesis. However, the clinicopathologic significance of RBBP6 expression in colon cancer is unknown; in particular, the prognostic value of RBBP6 combined with TP53...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Jian, Tang, Huamei, Wu, Zehua, Zhou, Chongzhi, Jiang, Tao, Xue, Yingming, Huang, Guoyu, Yan, Dongwang, Peng, Zhihai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3684577/ https://www.ncbi.nlm.nih.gov/pubmed/23799110 http://dx.doi.org/10.1371/journal.pone.0066524

Ejemplares similares

Zinc-α-2-Glycoprotein: A Candidate Biomarker for Colon Cancer Diagnosis in Chinese Population
por: Xue, Yingming, et al.
Publicado: (2014)

Rbbp4 loss disrupts neural progenitor cell cycle regulation independent of Rb and leads to Tp53 acetylation and apoptosis
por: Schultz‐Rogers, Laura E., et al.
Publicado: (2022)

S127: DELTATP73 IMPOSES TP53 MUTANT-LIKE PHENOTYPES INCLUDING DRUG RESISTANCE AND POOR PROGNOSIS ON TP53-WILD TYPE ACUTE MYELOID LEUKEMIA.
por: Pereira-Martins, Diego A, et al.
Publicado: (2023)

High-level expression of P21-Cdc/Rac-activated kinase 7 is closely related to metastatic potential and poor prognosis of colon carcinoma
por: Li, Chao, et al.
Publicado: (2016)

Correction: High-level expression of P21-Cdc/Rac-activated kinase 7 is closely related to metastatic potential and poor prognosis of colon carcinoma
por: Li, Chao, et al.
Publicado: (2017)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

Prognosis value of RBBP8 expression in plasma cell myeloma
por: Zhang, Weilong, et al.
Publicado: (2019)

Wild-Type TP53 Predicts Poor Prognosis in Patients with Gastric Cancer
por: Deng, Wenhong, et al.
Publicado: (2021)

Tp53 disruptions: is there a marker of poor prognosis in chronic lymphoproliferative disorders?
por: Cencini, Emanuele, et al.
Publicado: (2021)

Genetic alterations of KRAS and TP53 in intrahepatic cholangiocarcinoma associated with poor prognosis
por: Peng, Jianbo, et al.
Publicado: (2023)

TP53 and TP53-associated genes are correlated with the prognosis of paediatric neuroblastoma
por: Wang, Haiwei, et al.
Publicado: (2022)

Overexpression of GRK3, Promoting Tumor Proliferation, Is Predictive of Poor Prognosis in Colon Cancer
por: Jiang, Tao, et al.
Publicado: (2017)

TP53 R273C Mutation Is Associated With Poor Prognosis in LGG Patients
por: Zhang, Jian, et al.
Publicado: (2022)

RBBP6 induces non-small cell lung cancer cell proliferation and high expression is associated with poor prognosis
por: Wang, Qiu-Shi, et al.
Publicado: (2020)

Corrigendum to “Overexpression of GRK3, Promoting Tumor Proliferation, Is Predictive of Poor Prognosis in Colon Cancer”
por: Jiang, Tao, et al.
Publicado: (2020)

Concurrent TP53 mutations predict a poor prognosis of EGFR-mutant NSCLCs treated with TKIs: An updated systematic review and meta-analysis
por: Lan, Bo, et al.
Publicado: (2022)

Regulators of Oncogenic Mutant TP53 Gain of Function
por: Yamamoto, Satomi, et al.
Publicado: (2018)

STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma
por: Lobello, Cosimo, et al.
Publicado: (2020)

TP53 Mutation Infers a Poor Prognosis and Is Correlated to Immunocytes Infiltration in Breast Cancer
por: Zhang, Ziwen, et al.
Publicado: (2021)

Alterations of TP53 in microdissected transitional cell carcinoma of the human urinary bladder: high frequency of TP53 accumulation in the absence of detected mutations is associated with poor prognosis.
por: Abdel-Fattah, R., et al.
Publicado: (1998)

Different TP53 mutants in p53 overexpressed epithelial ovarian carcinoma can be associated both with altered and unaltered glycolytic and apoptotic profiles
por: Antoun, Stephanie, et al.
Publicado: (2018)

The arsenal of TP53 mutants therapies: neoantigens and bispecific antibodies
por: Yang, Chang, et al.
Publicado: (2021)

Therapeutic targeting of BRCA1 and TP53 mutant breast cancer through mutant p53 reactivation
por: Na, Bing, et al.
Publicado: (2019)

RBBP6 increases radioresistance and serves as a therapeutic target for preoperative radiotherapy in colorectal cancer
por: Xiao, Chao, et al.
Publicado: (2018)

Developmental pluripotency-associated 4: a novel predictor for prognosis and a potential therapeutic target for colon cancer
por: Zhang, Meng, et al.
Publicado: (2015)

A novel strategy for precise prognosis management and treatment option in colon adenocarcinoma with TP53 mutations
por: Niu, Lei, et al.
Publicado: (2023)

Loss of TP53 cooperates with c-MET overexpression to drive hepatocarcinogenesis
por: Zhou, Yi, et al.
Publicado: (2023)

Expression, purification, and characterisation of the p53 binding domain of Retinoblastoma binding protein 6 (RBBP6)
por: Russell, Bonnie L., et al.
Publicado: (2023)

Effects of the Mutant TP53 Reactivator APR-246 on Therapeutic Sensitivity of Pancreatic Cancer Cells in the Presence and Absence of WT-TP53
por: Abrams, Stephen L., et al.
Publicado: (2022)

Impact of TP53 mutations in breast cancer: Clinicopathological features and prognosisImpact of TP53 mutations in breast CA
por: Li, Xuerui, et al.
Publicado: (2020)

PAK6 increase chemoresistance and is a prognostic marker for stage II and III colon cancer patients undergoing 5-FU based chemotherapy
por: Chen, Jian, et al.
Publicado: (2014)

Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes
por: Sallman, David A., et al.
Publicado: (2021)

NEK2, a promising target in TP53 mutant cancer
por: Cusan, Martina, et al.
Publicado: (2022)

Mutant TP53 driving the Warburg Effect in Mantle Cell lymphoma
por: Kliebhan, Johannes, et al.
Publicado: (2022)

Non-chemotherapy adjuvant agents in TP53 mutant Ewing sarcoma
por: Kim, Jin-Ah, et al.
Publicado: (2023)

TP53 mutation predicts the poor prognosis of non-Hodgkin lymphomas: Evidence from a meta-analysis
por: Xu, Peipei, et al.
Publicado: (2017)

TP53 mutation variant allele frequency of ≥10% is associated with poor prognosis in therapy-related myeloid neoplasms
por: Shah, Mithun Vinod, et al.
Publicado: (2023)

Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
por: Tesio, Melania
Publicado: (2023)

KRT7 Overexpression is Associated with Poor Prognosis and Immune Cell Infiltration in Patients with Pancreatic Adenocarcinoma
por: Li, Yuexian, et al.
Publicado: (2021)

Specific TP53 Mutants Overrepresented in Ovarian Cancer Impact CNV, TP53 Activity, Responses to Nutlin-3a, and Cell Survival()
por: Mullany, Lisa K., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_44977tot8lamlfa16ajpiefs32